PTJ
VKTX icon

Paul Tudor Jones’s Viking Therapeutics VKTX Stock Holding History

Paul Tudor Jones’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,100
Closed -$231K – 4331
2026
Q1 		$231K Sell
7,100
-17,300
-71% -$556K ﹤0.01% 3296
2025
Q4 		$858K Buy
24,400
+11,600
+91% +$411K ﹤0.01% 2374
2025
Q3 		$336K Buy
+12,800
New +$382K ﹤0.01% 2910
2024
Q3 		– Sell
-10,600
Closed -$562K – 3149
2024
Q2 		$562K Buy
10,600
+800
+8% +$52.4K ﹤0.01% 1757
2024
Q1 		$804K Buy
+9,800
New +$436K 0.01% 1434

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Paul Tudor Jones's VKTX Position: Q2 2026 in Review

Paul Tudor Jones increased its Viking Therapeutics (VKTX) stake by 179% in Q2 2026, buying an estimated $4.09M and bringing the position to 197,331 shares worth $7.7M. The position accounts for 0.01% of the portfolio, ranked #988.

Paul Tudor Jones first reported a position in VKTX in Q4 2022 and has held it in 7 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Paul Tudor Jones held 197,331 shares of Viking Therapeutics worth $7.7M as of Q2 2026.
  • Paul Tudor Jones bought 126,542 Viking Therapeutics shares in Q2 2026, an estimated $4.09M.
  • Viking Therapeutics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #988 holding.
  • Paul Tudor Jones first reported a position in Viking Therapeutics in Q4 2022 and has held it in 7 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.